as 06-20-2025 4:00pm EST
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 439.8M | IPO Year: | N/A |
Target Price: | $45.00 | AVG Volume (30 days): | 2.0K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.21 | EPS Growth: | N/A |
52 Week Low/High: | $13.30 - $28.39 | Next Earning Date: | 04-30-2025 |
Revenue: | $4,828,000 | Revenue Growth: | 44.98% |
Revenue Growth (this year): | 35.98% | Revenue Growth (next year): | 115.38% |
PRTC Breaking Stock News: Dive into PRTC Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Business Wire
a month ago
Business Wire
a month ago
Business Wire
a month ago
Simply Wall St.
a month ago
GuruFocus.com
2 months ago
Business Wire
2 months ago
Business Wire
2 months ago
The information presented on this page, "PRTC PureTech Health plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.